Technical Data Sheet

Bispecific anti-mouse LAG3 x anti-mouse CTLA-4

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**CPB506**
Clone:	**Derived from clones C9B7W and 9D9**
Isotype:	Mouse IgG2a (LALA-PG), κ
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Mutations:	LALA-PG
Reported Applications:	ELISA For information on in-vivo applications, please contact technicalservice@bioxcell.com
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 μm filtration
Production:	Purified from mammalian cell supernatant in an animal-free facility
RRID:	
Molecular Weight:	135.7

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

CPB506 is a 1+1 bivalent bispecific checkpoint inhibitor antibody designed to target mouse lymphocyte-activation gene 3 (LAG3) and mouse cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4). CPB506 contains the murine IgG2a constant region to reduce immunogenicity and the formation of anti-drug antibodies (ADAs) in mouse models and LALA-PG Fc-silencing mutations to abolish antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) while minimizing Fc-driven off-target toxicity. CTLA-4 blockade reduces competition with CD28 for CD80/CD86, enhancing costimulatory signaling and promoting expansion and priming of effector T cells. LAG-3 is upregulated on chronically stimulated T cells and many intratumoral Tregs, where it dampens TCR signaling and contributes to exhaustion and reduced cytokine production. CPB506 is designed to simultaneously block two distinct inhibitory receptors and enrich bispecific concentration and potency to dual-positive cells in the tumor microenvironment to reinvigorate dysfunctional T cells and enhance antitumor T-cell responses while limiting systemic toxicity.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/cpb506?bxcs=9k1b3a#tab_references or scan the QR code below.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com